Sign in

CIK 0001847367 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

ALUMIS INC.

Sign in to watch
Ticker
ALMS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
650-231-6625
Business address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
Former names
FL2021-001, Inc.
  1. 4 Open-market buy 10% owner bought 72,212 shares at $7.38 ($532,925)
  2. 4 Open-market buy Director bought 125,743 shares at $7.20 ($905,350)
  3. 4 Open-market buy 10% owner bought 507,874 shares at an average $6.09 ($3,094,725)
  4. 4 Open-market buy 10% owner bought 507,874 shares at an average $6.09 ($3,094,725)
  5. 4 Open-market buy Director bought 507,874 shares at an average $6.09 ($3,094,725)
  6. 4 Open-market buy Director bought 241,338 shares at an average $6.34 ($1,529,865)
  7. 4 Open-market buy Director bought 276,179 shares at $5.25 ($1,449,940)
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Grant or award Chief Legal Officer acquired 10,000 shares (grant or award)
  14. 4 Grant or award SVP, People and Culture acquired 42,800 shares (grant or award)
  15. 4 Grant or award Chief Financial Officer acquired 28,000 shares (grant or award)
  16. 4 Grant or award Chief Business & Strategy Ofcr acquired 28,000 shares (grant or award)
  17. 4 Grant or award Chief Scientific Officer acquired 27,000 shares (grant or award)
  18. 4 Grant or award Chief Medical Officer acquired 25,450 shares (grant or award)
  19. 4 Grant or award Chief Development Officer acquired 26,750 shares (grant or award)
  20. 4 Derivatives Options or other derivatives

Page 3 of 6 · 114 filings